After a median follow-up of 15.1 months (IQR: 8.6–28.4 months), the mOS (24 months; 95% CI 19–43 months) for patients with viral HCC, CP class A liver disease, and treated with front-line ICI was significantly better than the mOS of patients with non-viral HCC (13 months; 95% CI: 9–27 months; P = 0.003; Fig. 3a). The gene discussed is CP; the disease is hepatocellular carcinoma.